Retatrutide Cuts Liver Fat Below Normal in 93% of Top-Dose Patients, Phase 2 Data Show
A Nature Medicine phase 2 study found retatrutide pushed liver fat below the 5% threshold in 93% of top-dose patients at 48 weeks, with no biopsies to confirm fibrosis reversal.